PF-562271

Catalog No.S2890

Molecular Weight(MW): 507.49

PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

Cited by 67 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Sci Signal, 2019, 12(565)

PubMed: 30670633 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):738

PubMed: 31570694 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1461-1469

PubMed: 31006845 ( click the link to review the publication )

Molecules, 2019, 24(10)

PubMed: 31109130 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, 168:163-173

PubMed: 30807921 ( click the link to review the publication )

Mol Med Rep, 2019, 19(6):4753-4760

PubMed: 31059085 ( click the link to review the publication )

Zygote, 2019, 27(3):173-179

PubMed: 31171046 ( click the link to review the publication )

Cell Rep, 2018, 22(10):2784-2796

PubMed: 29514104 ( click the link to review the publication )

Oncogene, 2018, 37(22):2953-2966

PubMed: 29515233 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):848

PubMed: 30154481 ( click the link to review the publication )

Cancer Sci, 2018, 109(12):3783-3793

PubMed: 30281878 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(18):e008604

PubMed: 30371220 ( click the link to review the publication )

J Cell Sci, 2018, 131(10)

PubMed: 29678906 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:2190657

PubMed: 30275837 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 10.1038/aps

PubMed: 29417941 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2325-2333

PubMed: 30106432 ( click the link to review the publication )
Cancer Epidemiol Biomarkers Prev, 2018, 27(7):805-813

PubMed: 29654156 ( click the link to review the publication )

Sci Transl Med, 2017, 9(420)

PubMed: 29237758 ( click the link to review the publication )

Nat Commun, 2017, 8:14122

PubMed: 28098159 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1347-1356

PubMed: 28406574 ( click the link to review the publication )

FEBS J, 2017, 284(17):2856-2869

PubMed: 28665039 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4032

PubMed: 28642549 ( click the link to review the publication )

Mol Carcinog, 2017, 56(12):2558-2565

PubMed: 28667800 ( click the link to review the publication )

Cancer Manag Res, 2017, 9:879-889

PubMed: 29276408 ( click the link to review the publication )

Cell Signal, 2017, 38:1-9

PubMed: 28647573 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):63-70

PubMed: 28560386 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5817-5826

PubMed: 29263678 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:4535326

PubMed: 29234400 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):8937-8943

PubMed: 28990104 ( click the link to review the publication )

Oncotarget, 2017, 8(43):75102-75113

PubMed: 29088849 ( click the link to review the publication )

Biophys J, 2017, 113(7):1585-1598

PubMed: 28844472 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(2):168-80

PubMed: 26689676 ( click the link to review the publication )

Nat Commun, 2016, 7:10354

PubMed: 26838601 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(23):5851-5863

PubMed: 27220963 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):81

PubMed: 27495308 ( click the link to review the publication )

Oral Oncology, 2016, 10.1016/j.oraloncology.2016.05.010

PubMed: ( click the link to review the publication )

Sci Rep, 2016, 6:36214

PubMed: 27796369 ( click the link to review the publication )

J Biol Chem, 2016, 291(15):8140-9

PubMed: 26865633 ( click the link to review the publication )
Mol Pharmacol, 2016, 89(5):521-40

PubMed: 26895766 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4369-4386

PubMed: 27762562 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 71:62-71

PubMed: 26693891 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48093-48106

PubMed: 27344177 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45186-45198

PubMed: 27286256 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(11):1412-21

PubMed: 26436690 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26274564 ( click the link to review the publication )

Oncogene, 2015, 34(40):5114-27

PubMed: 25639872 ( click the link to review the publication )

Cell Physiol Biochem, 2015, 37(2):515-26

PubMed: 26330161 ( click the link to review the publication )

J Biol Chem, 2015, 290(14):8677-92

PubMed: 25713079 ( click the link to review the publication )

Environ Toxicol Pharmacol, 2015, 39(1):114-24

PubMed: 25481308 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(20):E2595-601

PubMed: 25941386 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25755-69

PubMed: 26342198 ( click the link to review the publication )

Oncotarget, 2015, 6(3):1531-43

PubMed: 25605238 ( click the link to review the publication )

Environ Toxicol Pharm, 2014, 39(1):114-124

PubMed: 25481308 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Int J Clin Exp Pathol, 2013, 6(10):2082-91

PubMed: 24133586 ( click the link to review the publication )

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Description

Targets

FAK ^[1] (Cell-free assay)	PYK2 ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	CDK3/CyclinE ^[1] (Cell-free assay)	CDK1/CyclinB ^[1] (Cell-free assay)	View More
1.5 nM	13 nM	30 nM	47 nM	58 nM	View More

In vitro

PF-562271 binds in the ATP-binding cleft of FAK, forming two of the three “canonical” H-bonds between the inhibitor and main-chain atoms in the kinase hinge region. PF-562271 is potent in an inducible cell-based assay measuring phospho-FAK with IC50 of 5 nM. PF-562271 (3.3 μM) results in G1 arrest of PC3-M cells. ^[1] PF-562271 (1 nM) blocks bFGF-stimulated blood vessel angiogenesis as performed in chicken chorioallantoic membrane assays. PF-262271 potently blocks blood vessel sprouting without detectable changes in vascular leakage. ^[2] PF-562271 (250 nM) results in complete inhibition of collective A431 cell invasion into collagen gels. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
MV-4-11	MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrafYNHUUN3ME2wMlI4PjZizszN	NY\hUpRRW0GQR1XS
SW982	MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoK2TWM2OD1yLkOyPFIh\|ryP	M{HaVnNCVkeHUh?=
KM12	M{PBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[2TWM2OD1yLkO4OVU4KM7:TR?=	NFzs[oJUSU6JRWK=
COLO-205	M4WzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13tRmlEPTB;MD60PFY2QCEQvF2=	M{DqW3NCVkeHUh?=
COLO-829	M4PVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljjTWM2OD1yLke1NVc3KM7:TR?=	M4GxPXNCVkeHUh?=
MG-63	NUT6U3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLvTWM2OD1yLkiwOlM4KM7:TR?=	NEDHeHZUSU6JRWK=
IGROV-1	NFjZOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DkVWlEPTB;MD64NVA{QCEQvF2=	MXPTRW5ITVJ?
NCI-H650	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjyellKSzVyPUCuPFMyPTRizszN	MoHHV2FPT0WU
RT-112	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7JcXlKSzVyPUCuPVg1PiEQvF2=	MnXzV2FPT0WU
BCPAP	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17oWGlEPTB;MT6wNVI5QCEQvF2=	MWPTRW5ITVJ?
ALL-PO	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTFwMEG1PFQh\|ryP	NVjQPHFNW0GQR1XS
KYSE-270	M4q4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFwMES3NVQh\|ryP	NHfU[4VUSU6JRWK=
8305C	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTFwMEm5NFQh\|ryP	MWfTRW5ITVJ?
NCI-H810	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TVN2lEPTB;MT6xNFc4PiEQvF2=	MoTHV2FPT0WU
CAL-33	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnEfnRKSzVyPUGuNVI6OzhizszN	NXn2[XY5W0GQR1XS
AN3-CA	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TNSmlEPTB;MT6yNVg3PyEQvF2=	MYTTRW5ITVJ?
NKM-1	M4TDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXiWWlGUUN3ME2xMlI4PTB4IN88US=>	M4TCdnNCVkeHUh?=
BPH-1	NFKzc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTZSG5KSzVyPUGuNlg4PjZizszN	M1m3XHNCVkeHUh?=
MES-SA	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjjVG1KSzVyPUGuN\|A3QDJizszN	Mn3XV2FPT0WU
CAL-62	NGnidndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnftTWM2OD1zLkOxPVA6KM7:TR?=	M{LEOnNCVkeHUh?=
Detroit562	NYS2c5lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3r5emlEPTB;MT6zOVIzOiEQvF2=	NV20UXp1W0GQR1XS
KYSE-150	NG\lRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLUTWM2OD1zLkO1NlM3KM7:TR?=	NYP5UoVQW0GQR1XS
SK-UT-1	Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknYTWM2OD1zLkS0OlQ4KM7:TR?=	MnK0V2FPT0WU
HUTU-80	NWLjOoxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnviTWM2OD1zLkS0PFg3KM7:TR?=	M{HtOHNCVkeHUh?=
SIG-M5	NGXVW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1WyNGlEPTB;MT60PFM5PyEQvF2=	NY\YUGNIW0GQR1XS
AGS	NYLWOmF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjXTWM2OD1zLkWyNVI1KM7:TR?=	MoHhV2FPT0WU
ST486	NIPmRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTFwNUOyO\|gh\|ryP	NHLBcnNUSU6JRWK=
HSC-2	NGDyN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTFwNUO5OUDPxE1?	NITSSZNUSU6JRWK=
LCLC-103H	M1\XV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYG0VppPUUN3ME2xMlU2QDF6IN88US=>	MmHmV2FPT0WU
BC-1	Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjNO2tKSzVyPUGuOlE3PjRizszN	MYjTRW5ITVJ?
CGTH-W-1	NWL5bIlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFwNkG2O\|kh\|ryP	MXfTRW5ITVJ?
MZ1-PC	M2[5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LHOGlEPTB;MT62NlMyOiEQvF2=	MWTTRW5ITVJ?
SW1710	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXVTWM2OD1zLk[yOlI5KM7:TR?=	NG\3WFFUSU6JRWK=
EW-13	NYT6XGZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jETmlEPTB;MT62N\|Q3PiEQvF2=	NFvReZBUSU6JRWK=
TE-11	NF74Z45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTFwNkO1NlIh\|ryP	M4P4UXNCVkeHUh?=
BHY	NYnofVhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHu5bZpKSzVyPUGuOlU3PjNizszN	NUfrdmh2W0GQR1XS
ML-2	NHy4TVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTFwNk[4NFIh\|ryP	NW\xTIV3W0GQR1XS
MEL-JUSO	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTOTWM2OD1zLkeyPFkyKM7:TR?=	NVTnR\|U6W0GQR1XS
U251	M{XmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LP[2lEPTB;MT63OFA{OSEQvF2=	NV:2TGtOW0GQR1XS
MHH-ES-1	NGPxOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXNfZRFUUN3ME2xMlc6PTZ6IN88US=>	M{e5SnNCVkeHUh?=
CAL-85-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrjTWM2OD1zLkiwOFkh\|ryP	MYjTRW5ITVJ?
D-336MG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnoSXFWUUN3ME2xMlg2PjF2IN88US=>	MmrJV2FPT0WU
VA-ES-BJ	M33obmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnkTWM2OD1zLkmwN\|E2KM7:TR?=	MVnTRW5ITVJ?
MDA-MB-468	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTFwOUGyO\|Ih\|ryP	MlHRV2FPT0WU
MEL-HO	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlWxTWM2OD1zLkm3PVk{KM7:TR?=	NVjHV\|Y4W0GQR1XS
SW954	NGP6Z5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjOTWM2OD1{LkCwNVUyKM7:TR?=	NUj1WnVpW0GQR1XS
LB831-BLC	NFy5SllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3JN24xUUN3ME2yMlAxQTh6IN88US=>	NU\NZXZWW0GQR1XS
EW-16	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnLTWM2OD1{LkCzPVg{KM7:TR?=	MWfTRW5ITVJ?
NCI-H460	NWXWR5BOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonVTWM2OD1{LkC0PFM6KM7:TR?=	NH\CNnRUSU6JRWK=
CHP-212	M1PLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHW2SopKSzVyPUKuNFk2OzlizszN	NFnMTIhUSU6JRWK=
MHH-NB-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfPcnVKSzVyPUKuNVI5OThizszN	MX;TRW5ITVJ?
DU-4475	NILRWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTJwMUS3OVkh\|ryP	MWnTRW5ITVJ?
ABC-1	MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELVdYFKSzVyPUKuNlUyQTZizszN	NHfGV2xUSU6JRWK=
LOUCY	NXPyZlhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHOTYFiUUN3ME2yMlI3OTJ6IN88US=>	M3rHO3NCVkeHUh?=
LC-2-ad	NWDrVHN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTJwMk[5OlYh\|ryP	MnrVV2FPT0WU
ETK-1	NIjiNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH23fYVKSzVyPUKuNlg1PiEQvF2=	M{LJOnNCVkeHUh?=
KYSE-180	NYO2T2pLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LxNGlEPTB;Mj6yPFg4PCEQvF2=	NIrxR3RUSU6JRWK=
HOP-92	M{TleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTJwM{C2O\|Mh\|ryP	Mmr3V2FPT0WU
RCC10RGB	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TpT2lEPTB;Mj6zNlUxPyEQvF2=	NVzhUoVJW0GQR1XS
KASUMI-1	NUfqPXJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\UZmlEPTB;Mj6zNlg5KM7:TR?=	MYfTRW5ITVJ?
ACN	NVLqelRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jWPWlEPTB;Mj6zOFc1PSEQvF2=	NX;tXYFIW0GQR1XS
BxPC-3	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDBWWlKSzVyPUKuN\|U1OzZizszN	NF\WZXZUSU6JRWK=
MONO-MAC-6	M{P6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnrTolkUUN3ME2yMlQyOjR6IN88US=>	NHu0fI1USU6JRWK=
CAL-39	NUDOT\|NmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPyeHR3UUN3ME2yMlQyPjJ6IN88US=>	NWDzfVNLW0GQR1XS
CMK	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHETWM2OD1{LkSxO\|k2KM7:TR?=	NH;4VJpUSU6JRWK=
MFE-296	NYXnPVU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTVTWM2OD1{LkS3O\|kzKM7:TR?=	NGXKe4dUSU6JRWK=
DU-145	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnIc4ZuUUN3ME2yMlQ6OTF6IN88US=>	MoLFV2FPT0WU
MDA-MB-231	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nENWlEPTB;Mj60PVU4OiEQvF2=	NWPDNlFGW0GQR1XS
EFO-27	MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTxTWM2OD1{LkWxPFg5KM7:TR?=	NYHBR4c1W0GQR1XS
SNU-387	M4r6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3H5cGlEPTB;Mj61NlgzKM7:TR?=	NHX0N5BUSU6JRWK=
KYSE-410	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLHTWM2OD1{LkW2OVE4KM7:TR?=	M2LOPHNCVkeHUh?=
NCCIT	M4rHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnN[4ljUUN3ME2yMlU4OjRizszN	MmqwV2FPT0WU
LXF-289	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTJwNUiyO\|Mh\|ryP	NUjhOWtjW0GQR1XS
HMV-II	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTJwNUi5PVch\|ryP	MkjBV2FPT0WU
MOLT-4	MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPySWZuUUN3ME2yMlYxPzF{IN88US=>	NV3xN4NMW0GQR1XS
KOSC-2	NGH0XIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2e2Z2lEPTB;Mj62N\|g4QSEQvF2=	NGPy[VhUSU6JRWK=
TUR	NWq5fHR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrXTWM2OD1{Lk[1N\|Y6KM7:TR?=	M33RXHNCVkeHUh?=
NCI-H2087	NXzPfYw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTJwN{G2OFYh\|ryP	M1\OO3NCVkeHUh?=
SCC-15	M1TvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\JWGFOUUN3ME2yMlc2OjV{IN88US=>	MYHTRW5ITVJ?
HSC-4	NYLnfZBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTJwN{izPFkh\|ryP	M{HFRnNCVkeHUh?=
G-402	NWe1[Ws2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlKyTWM2OD1{LkixOFQ4KM7:TR?=	MUDTRW5ITVJ?
GP5d	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnqwTWM2OD1{LkizPFI4KM7:TR?=	MlnvV2FPT0WU
IGR-1	NEDv[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTJwOEO5PFch\|ryP	NWPZSJY5W0GQR1XS
SK-PN-DW	NIn2NJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLK[WNUUUN3ME2yMlg3OjB2IN88US=>	MlOwV2FPT0WU
OPM-2	NIWzWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTJwOEm5O\|gh\|ryP	MlvCV2FPT0WU
5637	NXfZSXA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2ToXmlEPTB;Mj65NlQ{QSEQvF2=	MlXQV2FPT0WU
NCI-H2030	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELuUmZKSzVyPUKuPVgxOjlizszN	MkDMV2FPT0WU
SK-LU-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjoOWFKSzVyPUKuPVg{OzRizszN	NYH6[YRsW0GQR1XS
EW-18	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTNwMEWzNkDPxE1?	MkPqV2FPT0WU
786-0	NX;LemZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPOTIJPUUN3ME2zMlA2Pzh2IN88US=>	NG\hRnhUSU6JRWK=
NCI-H1963	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTNwMEi4NlUh\|ryP	NV\lcJRGW0GQR1XS
A2780	NUXGRXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTNwMUCzOFEh\|ryP	NFnyUYxUSU6JRWK=
NCI-H526	M2HCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;j[ZNxUUN3ME2zMlE{QTZzIN88US=>	Mn25V2FPT0WU
BHT-101	M1:1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnlb\|VKSzVyPUOuNVU4QThizszN	MkD5V2FPT0WU
RPMI-7951	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrQb5pKSzVyPUOuNlAyOzdizszN	NU[4O3FOW0GQR1XS
HL-60	NXm0e5FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mof6TWM2OD1\|LkKxNVQh\|ryP	NX\1S3llW0GQR1XS
CTV-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTNwMkWzO\|ch\|ryP	NH\HfplUSU6JRWK=
IST-SL1	NF\DSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTNwMkm0OlUh\|ryP	MkD5V2FPT0WU
G-401	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTNwMkm4NFgh\|ryP	MWTTRW5ITVJ?
OVCAR-5	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYC2Wo5nUUN3ME2zMlM3OzV{IN88US=>	M1PqTnNCVkeHUh?=
EW-1	M1K1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHLTWM2OD1\|LkSwOVQ1KM7:TR?=	NFXZc45USU6JRWK=
H4	NV3YT\|l{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{OwfmlEPTB;Mz60O\|U3QSEQvF2=	MoDuV2FPT0WU
EM-2	NVjo[odwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXaTWM2OD1\|LkS4Olc1KM7:TR?=	MVrTRW5ITVJ?
RS4-11	M4eyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTCdWRKSzVyPUOuOFg4OTVizszN	M{LMWHNCVkeHUh?=
NOMO-1	NVfUdJZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nVXGlEPTB;Mz60PVIxPCEQvF2=	NV3lXFVNW0GQR1XS
HCT-116	NXrPPXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlm1TWM2OD1\|LkWwO\|EyKM7:TR?=	MXfTRW5ITVJ?
CAL-120	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHGTWM2OD1\|LkW3N\|Uh\|ryP	M2TIWXNCVkeHUh?=
CAL-51	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfMTWM2OD1\|LkW3OlEzKM7:TR?=	MXrTRW5ITVJ?
RVH-421	NXiwTZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PsS2lEPTB;Mz62NFMyOSEQvF2=	Mkm5V2FPT0WU
NCI-H2081	NYT2TnFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TwVWlEPTB;Mz62OVI5QCEQvF2=	M3PibXNCVkeHUh?=
SBC-5	NX\tU2Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDrNWNnUUN3ME2zMlY4QDh{IN88US=>	Mli0V2FPT0WU
RL95-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF72epNKSzVyPUOuO\|E5PjRizszN	NUDWPZpJW0GQR1XS
SW872	NVWzUoFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljoTWM2OD1\|Lke2PVU5KM7:TR?=	MUXTRW5ITVJ?
VM-CUB-1	M1HnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HLXGlEPTB;Mz63O\|UyKM7:TR?=	M1PxVXNCVkeHUh?=
SUP-T1	M{C0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fvNmlEPTB;Mz63PFMzKM7:TR?=	NY\EZVlsW0GQR1XS
697	NUTDZ5Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7pW2hsUUN3ME2zMlgyPjV5IN88US=>	MXLTRW5ITVJ?
DBTRG-05MG	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\w[Fk3UUN3ME2zMlgyPjd4IN88US=>	Mn\nV2FPT0WU
TE-441-T	M3HNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTNwOEK5N{DPxE1?	NE\sbJlUSU6JRWK=
A204	M2W4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\TfnVPUUN3ME2zMlkxQTV4IN88US=>	MVjTRW5ITVJ?
HCC2998	M2ixeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rkRmlEPTB;Mz65OFg1OyEQvF2=	NXyydY57W0GQR1XS
SCC-4	MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\PUnhkUUN3ME2zMlk2Pzh{IN88US=>	NUe3VHpqW0GQR1XS
ACHN	NIL6UmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDTOnFKSzVyPUSuNFI{PyEQvF2=	MVTTRW5ITVJ?
NB1	M172emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDkRZBKSzVyPUSuNFY3PDRizszN	MWLTRW5ITVJ?
PANC-08-13	NXPQd4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTRwMEe3N{DPxE1?	MVnTRW5ITVJ?
A4-Fuk	MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPiVJl6UUN3ME20MlA4QDZzIN88US=>	MmDpV2FPT0WU
NCI-H747	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;v[2lEPTB;ND6wPFY4PCEQvF2=	MXHTRW5ITVJ?
G-361	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLKTWM2OD12LkC5NFYh\|ryP	NYnhc4NCW0GQR1XS
NCI-H292	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTGTWM2OD12LkC5OFI6KM7:TR?=	NILncm5USU6JRWK=
HGC-27	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jsVWlEPTB;ND6wPVU1QSEQvF2=	NGLPXm1USU6JRWK=
ATN-1	MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTRwMUC3O\|ch\|ryP	NVf0PWQ3W0GQR1XS
RPMI-2650	M{fpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DBTmlEPTB;ND6xNlk4PSEQvF2=	MYTTRW5ITVJ?
SIMA	NVLqOWFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvvPZZKSzVyPUSuNVQ1KM7:TR?=	NEXmXJhUSU6JRWK=
CA46	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fh[2lEPTB;ND6xOlExPCEQvF2=	NEHnfpVUSU6JRWK=
CHL-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXxTWM2OD12LkG4PVYyKM7:TR?=	MUTTRW5ITVJ?
TE-10	NW\ibJNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofaTWM2OD12LkKyPFg4KM7:TR?=	MWDTRW5ITVJ?
NCI-H1734	NXHRTppRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTRwMk[2PVUh\|ryP	NEfCNWpUSU6JRWK=
DV-90	NInlb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\LTWM2OD12LkK5N\|k4KM7:TR?=	MXPTRW5ITVJ?
MOLT-16	M{DGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTkTWM2OD12LkOxNFE3KM7:TR?=	MYPTRW5ITVJ?
HuCCT1	M170Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrY[VlKSzVyPUSuN\|M4OjNizszN	NXTnO403W0GQR1XS
A3-KAW	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITiN4NKSzVyPUSuN\|U2PTJizszN	NVjlXnRXW0GQR1XS
HOS	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnTTWM2OD12LkO4OVY4KM7:TR?=	NYXLT4s4W0GQR1XS
KS-1	NV;ESW46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnibHJlUUN3ME20MlQzPDV7IN88US=>	NYW3ToxqW0GQR1XS
SNU-423	NYL4TpRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO4Z4hJUUN3ME20MlQzPjh3IN88US=>	NUTNSFhEW0GQR1XS
BC-3	M2TidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFf0SWpKSzVyPUSuOFM1PzdizszN	M3zC[nNCVkeHUh?=
SCC-9	M4XyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2n6cGlEPTB;ND60OFI6QSEQvF2=	M4e4NXNCVkeHUh?=
C8166	NYfU[phtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTRwNEe3OVMh\|ryP	M{POSnNCVkeHUh?=
NCI-H358	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTrPJRzUUN3ME20MlQ5PTN{IN88US=>	NXS2TXZjW0GQR1XS
GT3TKB	MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDaTWM2OD12LkS4PFIzKM7:TR?=	M3nNSXNCVkeHUh?=
NCI-SNU-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LSR2lEPTB;ND60PVcxOSEQvF2=	MYTTRW5ITVJ?
Ca9-22	NGSweFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITMN2lKSzVyPUSuOVU2OTZizszN	MmfRV2FPT0WU
L-363	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GwTWlEPTB;ND61OVk6PiEQvF2=	NGfMWnVUSU6JRWK=
Calu-1	NYG3S\|ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;zTWM2OD12LkW4O\|A4KM7:TR?=	MnnYV2FPT0WU
OE19	NEPXVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTRwNkOxOFUh\|ryP	NXfHO\|U1W0GQR1XS
COR-L23	M2PPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHSTFNUUUN3ME20MlY4OjhizszN	MUPTRW5ITVJ?
A431	MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTRwNkiyNlgh\|ryP	M{TYOXNCVkeHUh?=
MKN1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjQcHZKSzVyPUSuO\|A3PjVizszN	M4DHcHNCVkeHUh?=
SH-4	NXKxbJJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTRwN{K2N\|Mh\|ryP	NUfHeWNXW0GQR1XS
SNB75	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofXTWM2OD12Lke0OlYh\|ryP	MmfpV2FPT0WU
SW780	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTRwN{[4OFkh\|ryP	MVnTRW5ITVJ?
GOTO	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPOTWM2OD12Lke5Nlk{KM7:TR?=	NFX3RYhUSU6JRWK=
U-266	MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jDbWlEPTB;ND65OFkyQSEQvF2=	NVPC[YE1W0GQR1XS
KURAMOCHI	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHPOFJKSzVyPUWuNFI5OzRizszN	M33ocXNCVkeHUh?=
NMC-G1	NV[1OI93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTVwMEmxN\|kh\|ryP	NVLVcYpSW0GQR1XS
COLO-684	NVLXfmgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUW5eZJ4UUN3ME21MlI2OzdzIN88US=>	MYnTRW5ITVJ?
NTERA-S-cl-D1	M17semdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjVWWdKSzVyPUWuNlkzOThizszN	NYPvOHVZW0GQR1XS
RD	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfadmNHUUN3ME21MlI6PzdzIN88US=>	NY\HUWs4W0GQR1XS
A2058	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrNdW5KSzVyPUWuN\|A1OzhizszN	MX;TRW5ITVJ?
NCI-H2009	NF;rR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEeybXBKSzVyPUWuN\|A2OzhizszN	NY\4XnRLW0GQR1XS
8-MG-BA	M13HSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDjTWM2OD13LkO3NFc4KM7:TR?=	NXL6O\|dbW0GQR1XS
LC4-1	M1rQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGr4bndKSzVyPUWuN\|k{ODNizszN	NYHnXXR1W0GQR1XS
A101D	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTVwM{m2PFkh\|ryP	MnzlV2FPT0WU
ES8	NGrVfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1e0TmlEPTB;NT60NVQxQSEQvF2=	MWLTRW5ITVJ?
SF126	M1LqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHT1XI5KSzVyPUWuOFE1PjVizszN	M1rlPHNCVkeHUh?=
GDM-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvlT5l7UUN3ME21MlQyPzhzIN88US=>	NIXX[nFUSU6JRWK=
TE-6	NUX1[Y1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnoNGZKSzVyPUWuOFQ2PjlizszN	MV3TRW5ITVJ?
SR	NEPEcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTVwNUO2OFUh\|ryP	MUHTRW5ITVJ?
HOP-62	M{\YNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTVwNU[4PFch\|ryP	NYLuNmtCW0GQR1XS
HCC2157	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13MTGlEPTB;NT61Olg6PiEQvF2=	MonzV2FPT0WU
TE-15	MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTVwNUe3O\|kh\|ryP	MWDTRW5ITVJ?
BFTC-905	NGDOV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1Hi[WlEPTB;NT62NFQzOSEQvF2=	NGq5cnFUSU6JRWK=
TE-9	M3zZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjaPGE1UUN3ME21MlYyPzh6IN88US=>	NIfYe41USU6JRWK=
647-V	NV;3e\|ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTVwNkKwOFIh\|ryP	NEi5WnhUSU6JRWK=
KG-1	M1PJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjmTWM2OD13Lke0NFA2KM7:TR?=	NEjHdIxUSU6JRWK=
KYSE-510	MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NICydXRKSzVyPUWuO\|k2QDFizszN	M2rmfHNCVkeHUh?=
SK-MES-1	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLFXmw4UUN3ME21Mlg2QDlzIN88US=>	NWLRSlVHW0GQR1XS
OVCAR-3	M2e5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXofYh2UUN3ME21Mlg5OjB4IN88US=>	NF\iTWdUSU6JRWK=
LB1047-RCC	M1vCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3EWGhKSzVyPUWuPVAyPDhizszN	NFTHSI5USU6JRWK=
HEL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPibmVKSzVyPU[uNFIyQDhizszN	MV7TRW5ITVJ?
KARPAS-45	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\QXGxmUUN3ME22MlA{Pzh5IN88US=>	M2fnT3NCVkeHUh?=
NCI-H1304	NWHMVHhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjOTlZXUUN3ME22MlEzPDl5IN88US=>	MnL1V2FPT0WU
PC-3	M1riNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWK3NGh2UUN3ME22MlE{ODd{IN88US=>	M1TDdXNCVkeHUh?=
Calu-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPRe5lKSzVyPU[uNVQ3QDlizszN	NFj5T5lUSU6JRWK=
NCI-H1648	NUTiZ\|dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2i3W2lEPTB;Nj6xOVE3KM7:TR?=	NV;TZo1SW0GQR1XS
HSC-3	NVr1d4h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\Yc\|JKSzVyPU[uNVc{QTZizszN	MkCxV2FPT0WU
COLO-824	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTZwMke4Olgh\|ryP	NYrFUVIzW0GQR1XS
COLO-680N	MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWWwbIhkUUN3ME22MlM4PjN6IN88US=>	M2f4VHNCVkeHUh?=
SK-NEP-1	NX;udnk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLXS5RKSzVyPU[uOFA{PiEQvF2=	MnfzV2FPT0WU
SCC-25	NEDXbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;KR\|RtUUN3ME22MlQzPDl\|IN88US=>	NXnKUJc4W0GQR1XS
SF295	MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\SXWFKSzVyPU[uOFQ6QCEQvF2=	Mn;RV2FPT0WU
no-10	NGnHSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTZwNEe4OEDPxE1?	Mkn2V2FPT0WU
NCI-H838	NVXRU3R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nwd2lEPTB;Nj61NVcxOyEQvF2=	MVTTRW5ITVJ?
M059J	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXWTWM2OD14LkW1OlI2KM7:TR?=	NF7tU25USU6JRWK=
Calu-6	NE\wWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7Y[JFKSzVyPU[uOlU1OzVizszN	NHX4cXBUSU6JRWK=
TE-12	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jHemlEPTB;Nj63NlM4PyEQvF2=	NYnoe2J4W0GQR1XS
639-V	NIn1TVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTZwN{WxNlch\|ryP	NFrNdIJUSU6JRWK=
ESS-1	MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\Ye3ozUUN3ME22Mlc3ODd{IN88US=>	MUXTRW5ITVJ?
C-4-II	NV31UHZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4npdmlEPTB;Nj64N\|EyPyEQvF2=	MkDMV2FPT0WU
23132-87	NVnIbWRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPWTWM2OD14LkmwPVAyKM7:TR?=	NUmxWIYyW0GQR1XS
MEG-01	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVL0VYNlUUN3ME22Mlk{PTR4IN88US=>	NVW4e2hNW0GQR1XS
GI-1	M4PhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7hN3J[UUN3ME22Mlk1OzR6IN88US=>	MoDIV2FPT0WU
NCI-H2347	NITJV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFSyWGRKSzVyPU[uPVQ4OTVizszN	MYHTRW5ITVJ?
MS-1	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTzR4tZUUN3ME22Mlk2OTl{IN88US=>	MVjTRW5ITVJ?
SK-MEL-30	M3zU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjOWZNSUUN3ME22Mlk3OzF3IN88US=>	MVvTRW5ITVJ?
YKG-1	NXfRSlMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHkTWM2OD15LkCyOlc5KM7:TR?=	MUjTRW5ITVJ?
HT-3	M1XkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfVXYJKSzVyPUeuNFM1QSEQvF2=	MorHV2FPT0WU
NCI-H2126	M3;KNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4j5eGlEPTB;Nz6wPVc6OSEQvF2=	MnrWV2FPT0WU
GI-ME-N	NV31U3N7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\BdGVKSzVyPUeuNVY6ODZizszN	NIL1[5FUSU6JRWK=
LB771-HNC	M3:2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\LcJlWUUN3ME23MlE5ODN6IN88US=>	NEG5[nRUSU6JRWK=
LCLC-97TM1	NHTMdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGn1dJBKSzVyPUeuNlEzPzNizszN	NHn4N2VUSU6JRWK=
HO-1-N-1	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7mdYlpUUN3ME23MlI1ODJ2IN88US=>	M4L5XHNCVkeHUh?=
HCC1143	MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PLSGlEPTB;Nz6zO\|g6QCEQvF2=	MXPTRW5ITVJ?
HuO9	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M375V2lEPTB;Nz60PFc6PCEQvF2=	NYfGZ2w6W0GQR1XS
IST-SL2	NGfZdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXETWM2OD15LkWyNlczKM7:TR?=	M{fWRXNCVkeHUh?=
MLMA	MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrTTWM2OD15LkW0Olg6KM7:TR?=	NH:zWWVUSU6JRWK=
22RV1	NGjLc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknLTWM2OD15Lk[3PVc2KM7:TR?=	MXnTRW5ITVJ?
ONS-76	NXPQNWNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTdwNkm0NVYh\|ryP	NHvXRpdUSU6JRWK=
ECC12	NYjnSmY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XRSGlEPTB;Nz63NlkxOSEQvF2=	MlnYV2FPT0WU
HT-1080	MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXXTWM2OD15Lke4OVU2KM7:TR?=	M1Ty[3NCVkeHUh?=
SF268	M1e2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XwVmlEPTB;Nz64N\|U3KM7:TR?=	M4SyVHNCVkeHUh?=
COLO-800	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTdwOUC2PFUh\|ryP	NVHGSXZsW0GQR1XS
BB30-HNC	NW\TRYJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\PSW9MUUN3ME23Mlk1PTV\|IN88US=>	M3HBcXNCVkeHUh?=
CAKI-1	M1jlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYL2c2F{UUN3ME24MlA3PTJzIN88US=>	MkHtV2FPT0WU
GCIY	M2POS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPiVmFKSzVyPUiuNlM4OTNizszN	NFr0SHhUSU6JRWK=
MKN28	M3Tyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;5fXRKSzVyPUiuNlQ2QThizszN	MnjpV2FPT0WU
IPC-298	NWP1S3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33wO2lEPTB;OD6yO\|cxQSEQvF2=	MkLMV2FPT0WU
NCI-H1650	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDiTGdKSzVyPUiuNlkyQDVizszN	MonPV2FPT0WU
KP-N-YS	M1;OTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHGVZNKSzVyPUiuNlk{ODhizszN	NVvGRYZGW0GQR1XS
J82	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoezTWM2OD16LkO0NVI1KM7:TR?=	NVO5WWhyW0GQR1XS
SK-HEP-1	NVTu[HZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRThwM{W3NlMh\|ryP	MXXTRW5ITVJ?
PANC-03-27	NWHjdlN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;kVVlKSzVyPUiuN\|Y6OiEQvF2=	M3;2cnNCVkeHUh?=
KP-4	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\yO2lEPTB;OD60NVg2OyEQvF2=	M2XL[XNCVkeHUh?=
RERF-LC-MS	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XUdGlEPTB;OD60PFU6PSEQvF2=	M{XIUnNCVkeHUh?=
C-33-A	NF\SNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfxVGRKSzVyPUiuOlE2OjlizszN	NWfSRWVkW0GQR1XS
PA-1	MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfhS\|dKSzVyPUiuOlY3QTRizszN	MmHKV2FPT0WU
TE-5	M2fH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LXRmlEPTB;OD63NFI6PiEQvF2=	NFTGW5ZUSU6JRWK=
MHH-PREB-1	NWf3T4FqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;kPGlEPTB;OD63N\|ExPyEQvF2=	MXzTRW5ITVJ?
C3A	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFi0NpFKSzVyPUiuO\|Y2PjFizszN	NXrDUVJ5W0GQR1XS
SK-OV-3	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHtT3pUUUN3ME24Mlc6Pzd{IN88US=>	M1;OZnNCVkeHUh?=
AM-38	NUW1OYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTXd3hKSzVyPUiuPFA1OzlizszN	NEXxWGxUSU6JRWK=
LoVo	M4r0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRThwOUW1OlYh\|ryP	NUPjWWkyW0GQR1XS
MKN45	NED3bmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfEOJBCUUN3ME24Mlk3ODZ\|IN88US=>	M17hO3NCVkeHUh?=
NH-12	M171XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTlwMEK1OFIh\|ryP	M3uwZnNCVkeHUh?=
CAMA-1	NHjHNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTlwME[wNVIh\|ryP	NGnIVW9USU6JRWK=
HT-29	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHzTWM2OD17LkGyN\|c{KM7:TR?=	Ml7nV2FPT0WU
DMS-273	M2DrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjVUoo5UUN3ME25MlEzPSEQvF2=	NVHWXFlCW0GQR1XS
NCI-H719	M3LPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MormTWM2OD17LkG4N\|kyKM7:TR?=	MVPTRW5ITVJ?
SF539	M4XmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTlwMkGwPVgh\|ryP	MXzTRW5ITVJ?
Daoy	M4fWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTlwMkSxOFMh\|ryP	Mmn3V2FPT0WU
HCC70	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Lu[2lEPTB;OT6yO\|MxQSEQvF2=	MmHhV2FPT0WU
MFH-ino	NYTlbVBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDke41TUUN3ME25MlI6ODB5IN88US=>	NYi1O3dmW0GQR1XS
UACC-62	M3vGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTlwM{eyPVch\|ryP	NWX1SXRyW0GQR1XS
C2BBe1	M4nsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPyTWM2OD17LkO5OlUzKM7:TR?=	NH;oe3lUSU6JRWK=
KNS-42	NWjUWXNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHntd4NKSzVyPUmuOFM1ODdizszN	MnX2V2FPT0WU
SK-LMS-1	NIDiPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTlwN{W1N\|Uh\|ryP	MoLzV2FPT0WU
SK-CO-1	NIXwZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnz5TWM2OD17Lke2NlM2KM7:TR?=	MoG3V2FPT0WU
SN12C	NF;pR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfZTWM2OD17Lke2PFA3KM7:TR?=	Mk\NV2FPT0WU
HTC-C3	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHGNo9JUUN3ME25Mlc4QTh2IN88US=>	M2jEXXNCVkeHUh?=
OVCAR-4	NVOyXFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTlwOES4Nlgh\|ryP	M3;1UXNCVkeHUh?=
CHP-126	NYfMZ3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHZNFdKSzVyPUmuPVMzQSEQvF2=	M2LsVHNCVkeHUh?=
NCI-H716	M3zrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3aNVRKSzVyPUmuPVM{OjJizszN	M{PmWXNCVkeHUh?=
U-698-M	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\6e2lEPTB;OT65PVch\|ryP	M4DIN3NCVkeHUh?=
EFO-21	NVjnTJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDDWVZmUUN3ME2xNE4xODl\|IN88US=>	NFnQbXNUSU6JRWK=
RXF393	NFvQfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjPcXBKSzVyPUGwMlE{QTJizszN	NIHwN2lUSU6JRWK=
ChaGo-K-1	NUn0Oms{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIOyXW9KSzVyPUGwMlE4PzZizszN	MoHuV2FPT0WU
SJRH30	NW\vSlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljETWM2OD1zMD6xPFQ1KM7:TR?=	MXTTRW5ITVJ?
LU-65	NHjBdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\5ZZJKSzVyPUGwMlI6PDNizszN	MnnmV2FPT0WU
OS-RC-2	NFXu[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX76SHNGUUN3ME2xNE4{OjJ5IN88US=>	M{nqe3NCVkeHUh?=
YT	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HiPWlEPTB;MUCuOFAxOSEQvF2=	NH6zR4VUSU6JRWK=
COLO-679	NEXVXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvacXk{UUN3ME2xNE41Ojh3IN88US=>	MnXRV2FPT0WU
CAS-1	M37POmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[5bmlEPTB;MUCuOFYxQCEQvF2=	MYjTRW5ITVJ?
NCI-H2052	Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFyLkWxNFUh\|ryP	NHywSXVUSU6JRWK=
NCI-H2452	NFjSOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTFyLk[xPFEh\|ryP	NIH5[VZUSU6JRWK=
SW13	M1jKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPuZlNKSzVyPUGwMlY{PzRizszN	NIH0bYhUSU6JRWK=
HuP-T4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTFyLkewOlgh\|ryP	MXHTRW5ITVJ?
UMC-11	NUDTc4dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHZSJZKSzVyPUGwMlk{PzNizszN	NVrGR\|BmW0GQR1XS
EGI-1	MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnZR4NFUUN3ME2xNE46PDV3IN88US=>	MlHaV2FPT0WU
JiyoyeP-2003	NXnnUnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGq3OndKSzVyPUGxMlA5QTJizszN	MlHSV2FPT0WU
J-RT3-T3-5	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGqyb4NKSzVyPUGxMlEzODlizszN	M2Li[3NCVkeHUh?=
DoTc2-4510	NUfGVYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HoTWlEPTB;MUGuNVM5QSEQvF2=	NYX3U3UxW0GQR1XS
HLE	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYH2O4FwUUN3ME2xNU4zOTF7IN88US=>	M2X1ZXNCVkeHUh?=
SW626	NHz3ZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXuTJBKSzVyPUGxMlI5QDlizszN	MXTTRW5ITVJ?
COR-L105	NHP0PG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjIdJdoUUN3ME2xNU4{OjN5IN88US=>	NIrxZY5USU6JRWK=
ES6	M3vodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTFzLkW3OkDPxE1?	M13oXHNCVkeHUh?=
SNU-449	M1jnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTFzLk[wO\|Ih\|ryP	MVfTRW5ITVJ?
GR-ST	NF;DV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTFzLk[xPFEh\|ryP	MkK5V2FPT0WU
BL-41	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHaOZNOUUN3ME2xNU44OTd\|IN88US=>	MWDTRW5ITVJ?
GB-1	NU\KfY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTFzLke2NVkh\|ryP	NF22XnFUSU6JRWK=
COLO-320-HSR	NXu1XWxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXG4NXl3UUN3ME2xNU45PTF7IN88US=>	NGn6XHdUSU6JRWK=
L-540	NFPyPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjSbWJIUUN3ME2xNU45QTlizszN	MmriV2FPT0WU
NCI-H69	M3TxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjTc2V2UUN3ME2xNk4xOTN7IN88US=>	MVnTRW5ITVJ?
769-P	NHn4eIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTF{LkCxPUDPxE1?	MVrTRW5ITVJ?
A172	NWHKNHZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTF{LkGyNFch\|ryP	NGjidWRUSU6JRWK=
CAL-27	M4S4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTF{LkGzOlkh\|ryP	Mn7XV2FPT0WU
NCI-H1437	MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLVVoozUUN3ME2xNk4yPDR5IN88US=>	NELafG9USU6JRWK=
REH	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LvO2lEPTB;MUKuNVU4OyEQvF2=	MnHxV2FPT0WU
KINGS-1	MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITweGtKSzVyPUGyMlM1OjFizszN	MknmV2FPT0WU
NCI-H1792	M{\POWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTF{LkO4OVEh\|ryP	MoPvV2FPT0WU
SK-MM-2	M{HGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjvbW9KSzVyPUGyMlQxQDdizszN	MnXmV2FPT0WU
8505C	NXjLe2h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEK3[WZKSzVyPUGyMlYyOiEQvF2=	MXTTRW5ITVJ?
HAL-01	M4HhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TkUmlEPTB;MUKuOlE4PCEQvF2=	M2X2cnNCVkeHUh?=
NCI-H2141	NGHqbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIn5cXpKSzVyPUGyMlY2QCEQvF2=	NWLtPWJiW0GQR1XS
HCC1806	M2TJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTF{Lk[5OVIh\|ryP	NX7Vc2l2W0GQR1XS
LU-134-A	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHVPGhKSzVyPUGyMlk{KM7:TR?=	NWrJXIM2W0GQR1XS
HT	M2PLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTF{Lkm0N\|ch\|ryP	MUXTRW5ITVJ?
OE33	NEOzN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTF{Lkm0OVYh\|ryP	NWTZZ2xNW0GQR1XS
ES4	NGP6epJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DQVmlEPTB;MUKuPVQ5PyEQvF2=	NGTDN3VUSU6JRWK=
SW948	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\wUIVNUUN3ME2xN{4xOTNizszN	NFnFXG9USU6JRWK=
LB2241-RCC	MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\PTWM2OD1zMz6xOFY6KM7:TR?=	NFy4TZZUSU6JRWK=
CCF-STTG1	NYrJdI1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTF\|LkSwN\|kh\|ryP	NH;kdGVUSU6JRWK=
RPMI-8402	NYq0cpJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTF\|LkWwN\|Eh\|ryP	NV7sRWdHW0GQR1XS
DEL	M3\TUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7NTWM2OD1zMz61OVA{KM7:TR?=	MUjTRW5ITVJ?
NB5	NYn1SZljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TwSmlEPTB;MUOuOVUxOyEQvF2=	MWHTRW5ITVJ?
NUGC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTF\|Lke0OVMh\|ryP	MkjTV2FPT0WU
CAL-72	M2DyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIWzU3FKSzVyPUG0MlE6ODZizszN	M4PIPHNCVkeHUh?=
VMRC-RCZ	M1riTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTQdZVnUUN3ME2xOE4zOzZizszN	MXjTRW5ITVJ?
YAPC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTF2LkK0NFch\|ryP	MY\TRW5ITVJ?
ES5	NWC2[IVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HsVGlEPTB;MUSuNlU6QSEQvF2=	M4m1[3NCVkeHUh?=
CAL-12T	MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\M[mlEPTB;MUSuOFM{PiEQvF2=	M1LJNHNCVkeHUh?=
GAMG	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;rW5dKSzVyPUG0MlU2PzdizszN	MonKV2FPT0WU
BT-20	NG\RZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTF2LkmzPFQh\|ryP	NYThWHNLW0GQR1XS
KALS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHJTWM2OD1zNT6wNVU5KM7:TR?=	MUjTRW5ITVJ?
LS-123	NXHMVHNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHv2OY5KSzVyPUG1MlAyPjVizszN	NUjUbmFHW0GQR1XS
LK-2	Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEf2ZodKSzVyPUG1MlA5PjJizszN	MW\TRW5ITVJ?
NCI-H1770	NFvpTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTF3LkK4Olgh\|ryP	Mo\GV2FPT0WU
MIA-PaCa-2	NYDZcIdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PB[WlEPTB;MUWuOFE3OyEQvF2=	NXXnNZlHW0GQR1XS
DB	NU[3d3BqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrDTWM2OD1zNT62PVQyKM7:TR?=	M2TmRnNCVkeHUh?=
Becker	NWTrbYV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTnfGNYUUN3ME2xOU45QTJ4IN88US=>	NETTeo5USU6JRWK=
HT-144	NWLuOHN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTF3Lkm0PVch\|ryP	MoiyV2FPT0WU
NCI-H2405	NXzMPJVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTF4LkKyNVgh\|ryP	NXfMTm42W0GQR1XS
TK10	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4f3XWlEPTB;MU[uN\|c1OiEQvF2=	MYjTRW5ITVJ?
THP-1	M3flRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrTfoNvUUN3ME2xOk41PjZ3IN88US=>	MXHTRW5ITVJ?
LB373-MEL-D	MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1:2SWlEPTB;MU[uOlE{QCEQvF2=	MYTTRW5ITVJ?
SJSA-1	M1zncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7CbGNKSzVyPUG2MlkzOTlizszN	Mlq0V2FPT0WU
EB2	NWTHO3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfvVpJKSzVyPUG3Mlc1OjZizszN	NYTlWXZEW0GQR1XS
MN-60	NFnGdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4qzV2lEPTB;MUeuO\|k{PiEQvF2=	M{G2XHNCVkeHUh?=
A253	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7XOWFDUUN3ME2xO{45OjVizszN	NFPkdmRUSU6JRWK=
CESS	NGrVTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DqVGlEPTB;MUeuPVMzPiEQvF2=	NWLNT3RxW0GQR1XS
EW-11	NHfwdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTF5Lkm5OVgh\|ryP	MXPTRW5ITVJ?
TE-8	NEm2OIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDSc\|hKSzVyPUG4MlA3PjlizszN	MkjhV2FPT0WU
UACC-257	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Hv[2lEPTB;MUiuNlA3OiEQvF2=	MYfTRW5ITVJ?
NCI-H226	NYLkTVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;ETWM2OD1zOD64Nlk6KM7:TR?=	MX\TRW5ITVJ?
NCI-H748	M1zZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TvcmlEPTB;MUiuPFU5PSEQvF2=	NVrjNFNWW0GQR1XS
NCI-H1299	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTF6Lki5NVgh\|ryP	NF3GfZNUSU6JRWK=
IST-MEL1	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF7LkG3OVQh\|ryP	M1rodXNCVkeHUh?=
HCC1187	M2Dnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTF7LkG3PVYh\|ryP	M1HYSXNCVkeHUh?=
HT-1376	NXTldoNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDMcJFKSzVyPUG5MlIxOjlizszN	M3XS[XNCVkeHUh?=
SK-MEL-2	NITL[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;aTWM2OD1zOT6yNVU2KM7:TR?=	MUnTRW5ITVJ?
U031	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4riZWlEPTB;MUmuNlIyQSEQvF2=	MWPTRW5ITVJ?
NCI-H524	M1qyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XlcmlEPTB;MUmuOVczPSEQvF2=	MmLiV2FPT0WU
KU812	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zsemlEPTB;MUmuOVk1PCEQvF2=	M3\oTXNCVkeHUh?=
NB10	NVT5PFBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTF7Lk[yOlgh\|ryP	MkTsV2FPT0WU
NOS-1	M2rWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDXR\|RKSzVyPUKwMlE2PzdizszN	M1TN[XNCVkeHUh?=
EW-7	NWDtTmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjqTWM2OD1{MD6xOlI5KM7:TR?=	NHHJWnlUSU6JRWK=
Raji	NGDm[\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTJyLkK1Olgh\|ryP	MX3TRW5ITVJ?
LB2518-MEL	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3foWmlEPTB;MkCuN\|k2OyEQvF2=	NYrSUohEW0GQR1XS
PANC-10-05	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH61eXpKSzVyPUKwMlQ3OTNizszN	NV3rSW52W0GQR1XS
MZ2-MEL	NX\iPWN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTn[odtUUN3ME2yNE42QDF2IN88US=>	M3;4bnNCVkeHUh?=
MFE-280	M{ixUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTJzLkOxPFgh\|ryP	NYD1dmNWW0GQR1XS
RKO	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTJzLkOyNFIh\|ryP	NFeyN4dUSU6JRWK=
KMOE-2	M2DJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoO0TWM2OD1{MT6zNlg5KM7:TR?=	NGXxZ\|BUSU6JRWK=
K5	M4XWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnYd5lKSzVyPUKxMlM5QTNizszN	NWPxWm9jW0GQR1XS
NCI-H64	Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3qzZWlEPTB;MkGuOFc2PiEQvF2=	M4LOVXNCVkeHUh?=
K-562	NXe5[4NVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUT6dphDUUN3ME2yNU41QTdzIN88US=>	NVPGT2JXW0GQR1XS
HCE-T	NGTTU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj1TWM2OD1{MT61NFk1KM7:TR?=	M17iU3NCVkeHUh?=
COLO-792	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPvS\|ZKSzVyPUKxMlU5OjdizszN	NFn0RXNUSU6JRWK=
PFSK-1	MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTJzLk[4N\|ch\|ryP	MontV2FPT0WU
DOK	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfLbWFKSzVyPUKxMlc3QDdizszN	MYXTRW5ITVJ?
NCI-H1882	NID3PWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3XcHZKSzVyPUKxMlg2QTZizszN	MX\TRW5ITVJ?
KNS-81-FD	NX\FSYtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTHTWM2OD1{MT64OlMyKM7:TR?=	MVjTRW5ITVJ?
OCUB-M	NYTpeGM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\wVFV6UUN3ME2yNU46Pjh6IN88US=>	MXTTRW5ITVJ?
NCI-H1694	NYLicG9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTJzLkm4OlMh\|ryP	NWnybmpEW0GQR1XS
LS-513	M1LuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPzTWM2OD1{Mj6wN\|Y4KM7:TR?=	M3;2PXNCVkeHUh?=
NCI-H2122	NELqW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPOTWM2OD1{Mj6xOlc4KM7:TR?=	NVLOR2F3W0GQR1XS
IMR-5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3vXJF3UUN3ME2yNk4zQDdizszN	NEH3eoZUSU6JRWK=
SNU-C2B	MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DQVWlEPTB;MkKuOlc1PiEQvF2=	M{HvUXNCVkeHUh?=
A498	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTJ{LkixO\|ch\|ryP	Mkj4V2FPT0WU
NCI-H727	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1POcGlEPTB;MkKuPFg{PiEQvF2=	NVy5UWVZW0GQR1XS
SW1573	M4DVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLUTWM2OD1{Mz6wOlQ3KM7:TR?=	MVzTRW5ITVJ?
RO82-W-1	NETYco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXT1OpFpUUN3ME2yN{4zPTFzIN88US=>	NX[2c\|Q4W0GQR1XS
SKG-IIIa	M3fiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M335WmlEPTB;MkOuN\|U1PiEQvF2=	MW\TRW5ITVJ?
MC-CAR	NIjoWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEC0fW5KSzVyPUKzMlUyQDNizszN	NVO3O5ZOW0GQR1XS
NCI-H446	NHXUWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\Zd2lEPTB;MkOuOlA6OyEQvF2=	MnfwV2FPT0WU
PC-14	M3Tvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTJ\|Lk[2NlMh\|ryP	MlP4V2FPT0WU
TGBC1TKB	NX7OPFVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ\|Lke0OlEh\|ryP	NHvNOmVUSU6JRWK=
EFM-19	NFWzVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NESyXlVKSzVyPUK0MlE5PDRizszN	M1Kwd3NCVkeHUh?=
SK-N-DZ	NXjoTYJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjRV25DUUN3ME2yOE41QTd5IN88US=>	M1POT3NCVkeHUh?=
NCI-H661	NWHUSFN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3K5VGlEPTB;MkSuOVIyPyEQvF2=	NXLvfmIyW0GQR1XS
SW1990	NV[0RY4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LjN2lEPTB;MkSuOVg5OyEQvF2=	MVPTRW5ITVJ?
SW684	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzGTWM2OD1{ND63OlI1KM7:TR?=	Mo\HV2FPT0WU
Ca-Ski	NFy2NIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLiSoRKSzVyPUK0MlkzOzdizszN	NFPsXZVUSU6JRWK=
TGW	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnkTWM2OD1{NT6yN\|M4KM7:TR?=	MmC5V2FPT0WU
CaR-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\5V2hKSzVyPUK1MlM2PyEQvF2=	MX3TRW5ITVJ?
D-247MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[3TWM2OD1{NT60O\|Q{KM7:TR?=	NUXPT2FQW0GQR1XS
CCRF-CEM	NEPhdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XoZ2lEPTB;MkWuO\|Q2QSEQvF2=	MkLCV2FPT0WU
CAPAN-1	MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHyTWM2OD1{NT63OVAyKM7:TR?=	NVjyfGhLW0GQR1XS
CP50-MEL-B	M1PuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInrdGRKSzVyPUK1Mlk6ODFizszN	MVfTRW5ITVJ?
FADU	NYjzdlZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYH0cVl6UUN3ME2yOk42OTV{IN88US=>	M{L6VHNCVkeHUh?=
Daudi	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHqxeHVKSzVyPUK2MlUyPThizszN	MVjTRW5ITVJ?
U-87-MG	MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7XcnN4UUN3ME2yOk42OzB3IN88US=>	MULTRW5ITVJ?
DSH1	M4fjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjLTIlYUUN3ME2yOk42PDB4IN88US=>	NWe5NI41W0GQR1XS
KYSE-520	NXWzXYVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPPTWM2OD1{Nj61OVU{KM7:TR?=	M1fIOnNCVkeHUh?=
HuH-7	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkG3TWM2OD1{Nj65NFg3KM7:TR?=	MVrTRW5ITVJ?
U-2-OS	MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Tuc2lEPTB;MkeuNFI4OSEQvF2=	NYTUSJpQW0GQR1XS
LU-99A	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\Pe4VKSzVyPUK3MlE4PTRizszN	NEPhd4dUSU6JRWK=
T98G	M1HldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTJ5LkG5O\|Mh\|ryP	NIXzW5ZUSU6JRWK=
MZ7-mel	NUPEb2RqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTJ5LkW1OFgh\|ryP	MofvV2FPT0WU
SNU-C1	M1jzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHHN5VRUUN3ME2yO{43PDlzIN88US=>	NXy0V5d5W0GQR1XS
MDA-MB-175-VII	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTJ5Lk[5O\|Uh\|ryP	M37SO3NCVkeHUh?=
HuP-T3	M2rvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnXTWM2OD1{OD6wOFk2KM7:TR?=	M1K3UXNCVkeHUh?=
T-24	MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjQU\|dGUUN3ME2yPE4yQTJ3IN88US=>	NFrtV3JUSU6JRWK=
HDLM-2	NEe3S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jiXWlEPTB;MkiuNlQ2QSEQvF2=	MonrV2FPT0WU
NCI-H1651	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ns[GlEPTB;MkiuNlU6OiEQvF2=	NXXuRXNGW0GQR1XS
SK-N-AS	MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Dp[mlEPTB;MkiuN\|E4OSEQvF2=	NIWxRmFUSU6JRWK=
NY	M1HER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPP[VBKSzVyPUK4MlY2PzlizszN	NInvZ29USU6JRWK=
D-283MED	NVm2XGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rI[mlEPTB;MkiuPFcxQCEQvF2=	NVnZSmE4W0GQR1XS
KLE	M3LOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTJ6Lkm5NFYh\|ryP	NWW2SXhvW0GQR1XS
NCI-H28	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\SbWlEPTB;MkmuNFEzKM7:TR?=	MV3TRW5ITVJ?
TE-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTJ7LkKxOlch\|ryP	NUf0UlNQW0GQR1XS
SK-MEL-24	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHJZoMzUUN3ME2yPU42PDZ4IN88US=>	M1vIOXNCVkeHUh?=
CAL-54	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTUTWM2OD1{OT62NFQ3KM7:TR?=	NHP1NXdUSU6JRWK=
A673	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mon4TWM2OD1{OT63N\|Ih\|ryP	NWPpSpdEW0GQR1XS
HEC-1	NX\IdG9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTNyLkCwOVMh\|ryP	M{HGfnNCVkeHUh?=
LS-411N	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEj5flZKSzVyPUOwMlE1PzVizszN	MXPTRW5ITVJ?
SW962	NEj6OJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTUTWM2OD1\|MD6yOFc4KM7:TR?=	NWLTdo1ZW0GQR1XS
OVCAR-8	NUPYWGhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\hTWM2OD1\|MD62O\|k1KM7:TR?=	NFPKUpdUSU6JRWK=
NCI-H630	M1jINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTNyLki5OVMh\|ryP	NG\xV5JUSU6JRWK=
D-263MG	M{\DSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfSTWM2OD1\|MT6wOFI1KM7:TR?=	Ml;rV2FPT0WU
NCI-H596	Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjl[I5ZUUN3ME2zNU4xPjJzIN88US=>	NIDGe4FUSU6JRWK=
BB49-HNC	NInwXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn70TWM2OD1\|MT6xNVIh\|ryP	M1Hl[nNCVkeHUh?=
KYSE-70	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTNzLkOwNFgh\|ryP	MV3TRW5ITVJ?
LAN-6	NH;YcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTwTWM2OD1\|MT60PVkzKM7:TR?=	MkDDV2FPT0WU
NCI-H2228	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjW[JRKSzVyPUOxMlU3OjVizszN	NWLnbYxJW0GQR1XS
SW620	M2HIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfaTWM2OD1\|MT62Nlg{KM7:TR?=	M{PxSHNCVkeHUh?=
KM-H2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;iO2lEPTB;M{GuO\|MxPiEQvF2=	MWjTRW5ITVJ?
DJM-1	M1T2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zlb2lEPTB;M{KuNVM5PiEQvF2=	MVXTRW5ITVJ?
SW48	M1XqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTN{LkO4NlUh\|ryP	MnXRV2FPT0WU
NCI-H1793	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTN{Lk[xOlMh\|ryP	MnLkV2FPT0WU
LU-165	NXrDe4xsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LSemlEPTB;M{OuNFA5KM7:TR?=	NV\HcZdqW0GQR1XS
EHEB	NWTtSoxlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLTcJdSUUN3ME2zN{4xPDl2IN88US=>	M3K2PXNCVkeHUh?=
NCI-H441	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPi[IxKSzVyPUOzMlIzOzVizszN	MoCzV2FPT0WU
LOXIMVI	M3GzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTN\|LkO2O\|kh\|ryP	M4r2[HNCVkeHUh?=
MC-IXC	NHfyT\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUW4VJZ1UUN3ME2zN{42PjV3IN88US=>	NGr5c4RUSU6JRWK=
NCI-H522	Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHFcmdXUUN3ME2zN{43PTRizszN	M1jLbXNCVkeHUh?=
IA-LM	NXi1ZZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HFV2lEPTB;M{OuOlc1PiEQvF2=	M1vJe3NCVkeHUh?=
NCI-H1417	NF\mTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfLUWJKSzVyPUOzMlk2QDVizszN	MoPrV2FPT0WU
HCC2218	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrFRYV[UUN3ME2zOU4zOTh3IN88US=>	MlPYV2FPT0WU
HC-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj0eIpKSzVyPUO1MlQxOjRizszN	NWj4fFNJW0GQR1XS
HH	NHjPSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIG2RZVKSzVyPUO1MlQyPDFizszN	NVr1SIpbW0GQR1XS
EFE-184	NEXpTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTN3Lk[4Nlkh\|ryP	M4\6TXNCVkeHUh?=
NCI-H1355	M{TrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIGy[GpKSzVyPUO1Mlc4OThizszN	M{\qS3NCVkeHUh?=
BV-173	M4niXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnxNlVKSzVyPUO1MlgzPjRizszN	M{C5WXNCVkeHUh?=
NEC8	NFfEbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3YPJpKSzVyPUO2MlQ6OjRizszN	NIjvOmlUSU6JRWK=
SW1463	M{\CbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXqWZdOUUN3ME2zOk43PTZ4IN88US=>	NHi3eFdUSU6JRWK=
KYSE-140	NWjiWI9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUX0eYszUUN3ME2zOk44Ojl6IN88US=>	MYnTRW5ITVJ?
no-11	NIjSZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTN4Lki1N\|Yh\|ryP	NHHXOphUSU6JRWK=
HCC1937	NH\U[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTN5LkCxOVQh\|ryP	NGDE[lZUSU6JRWK=
LNCaP-Clone-FGC	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTN5LkG5NFMh\|ryP	MoP1V2FPT0WU
KARPAS-422	M2jIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvqPY5oUUN3ME2zO{41PDNzIN88US=>	Mm\RV2FPT0WU
RCM-1	NGL4PZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnGXmhsUUN3ME2zO{42OzV6IN88US=>	NVjIWod5W0GQR1XS
A375	NGH3TI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7KNYlKSzVyPUO3Mlc3PDdizszN	NXrmcVAxW0GQR1XS
TGBC24TKB	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkH5TWM2OD1\|OD6wNlM6KM7:TR?=	MVPTRW5ITVJ?
MDA-MB-453	NUK4TZpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PzS2lEPTB;M{muNFIyQCEQvF2=	NHLEdGJUSU6JRWK=
Capan-2	M4[zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXVTpdrUUN3ME2zPU4xPTB7IN88US=>	MXjTRW5ITVJ?
SW756	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LhXGlEPTB;M{muOVA6OSEQvF2=	MUHTRW5ITVJ?
KU-19-19	M2XPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGr3ZVVKSzVyPUO5MlYzQDJizszN	M2DXfnNCVkeHUh?=
NCI-H2170	MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjLc4g6UUN3ME2zPU46QTd5IN88US=>	NFzXWGFUSU6JRWK=
COLO-678	NX3QW2E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVP2UHA4UUN3ME20NE42QTVizszN	MWjTRW5ITVJ?
PF-382	MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV74R3gxUUN3ME20NE44PDh5IN88US=>	Mkn3V2FPT0WU
OAW-42	M4XRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXWTWM2OD12Mj6yPVQzKM7:TR?=	M{ewNnNCVkeHUh?=
LB996-RCC	MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrTN29KSzVyPUSyMlgxODhizszN	MkH6V2FPT0WU
SAS	NY\hVYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;PU3hNUUN3ME20N{41Ojh6IN88US=>	MW\TRW5ITVJ?
MRK-nu-1	NUHMN2RKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWP5SnNuUUN3ME20OE44PDF2IN88US=>	MYjTRW5ITVJ?
EoL-1-cell	NVXlXYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHQNm5KSzVyPUS0MlkyOzZizszN	M4r5bXNCVkeHUh?=
NCI-H2342	M1PoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTSTWM2OD12NT6xNVE4KM7:TR?=	M1SxSXNCVkeHUh?=
NCI-H1703	Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PhVWlEPTB;NE[uNFU6OiEQvF2=	NHfWPIVUSU6JRWK=
NCI-H187	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITad3ZKSzVyPUS2MlE5PjlizszN	MUXTRW5ITVJ?
CP66-MEL	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXixTYd7UUN3ME20Ok4zPzh7IN88US=>	MmC3V2FPT0WU
HCC1569	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLTW\|lKUUN3ME20Ok42QTF5IN88US=>	M1LCWXNCVkeHUh?=
BL-70	NVrmWo1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\1c4FIUUN3ME20Ok44PzN5IN88US=>	MkXtV2FPT0WU
Saos-2	NWHjWnVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NED3V21KSzVyPUS3MlMyOjNizszN	M1XMbHNCVkeHUh?=
LC-1F	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jifWlEPTB;NEeuOlExPSEQvF2=	MUDTRW5ITVJ?
KY821	NHz6blJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHVS2hFUUN3ME20O{43PDN2IN88US=>	M4TURXNCVkeHUh?=
PSN1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\QPY9KUUN3ME20PE4yPDBzIN88US=>	M1TSRXNCVkeHUh?=
RT4	M2T0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzNTWM2OD12OD64N\|c4KM7:TR?=	Mmj0V2FPT0WU
LS-1034	MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;iTWM2OD12OD64PVU1KM7:TR?=	NEnEbYJUSU6JRWK=
NCI-H1395	NF;RSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrWUYdKSzVyPUS5MlA1QTJizszN	NWGybVg2W0GQR1XS
EKVX	Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjOTHc4UUN3ME20PU43PzNzIN88US=>	MmfpV2FPT0WU
IST-MES1	NGjONFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTR7Lki5OFQh\|ryP	NWfvTYlRW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-FAK / FAK / p-Talin / Talin ; PubMed: 26530902 Cancer Res Dose response of PF-562271 on the phosphorylation of FAK-Y397 or Talin-S425 in PC3-mm2 cells. p-Src / Src / p-paxillin / Paxillin / ICAM-1 ; PubMed: 29417941 Acta Pharmacol Sin MDA-MB-231 cells transfected with FAK-specific siRNAs or treated for 12 h with PF-562271 at the indicated concentrations were subjected to immunoblotting with indicated antibodies.	26530902 29417941
Immunofluorescence	p-FAK; PubMed: 26530902 Cancer Res Immunostaining of PC3-mm2 cells showed that phosphorylated FAK is localized at focal adhesions (inset).	26530902
Growth inhibition assay	Cell viability; PubMed: 28953264 Nutrients MTT assay showed inhibition of cell proliferation and viability in HCT116 (B) and SW480 (D) cell lines treated with resveratrol and/or different concentrations of FAK-Inhibitor (PF-562271: 0.01, 0.1, 1, and 10 µM) cultured in monolayer for 12 h. Data shown are representative of three independent sets of experiments. Values were compared with the control and statistically significant values with p < 0.05 are designated by an asterisk () and p < 0.01 are designated by two asterisks (*).	28953264

In vivo

PF-562271 (< 33 mg/kg p.o.) inhibits FAK phosphorylation in tumors in a dose- and time-dependent manner in U87MG-bearing mice. PF-562271 (50 mg/kg p.o. bid) results in 86% tumor growth inhibition in BxPc3 xenografts mice and 45% tumor growth inhibition in PC3-M xenografts mice. PF-562271 (25 mg/kg, bid) results in 2-fold greater apoptosis in treated tumors in mice bearing H125 lung xenografts. ^[1] PF-562271 (33 mg/kg, p.o.) inhibits extensive movement of the tumor cells over 24 hours in mice. PF-562271 (33 mg/kg, p.o.) results in altered E-cadherin dynamics in mice, which correlates with reduced E-cadherin–dependent collective cell movement. ^[3] PF-562271 (25 mg/kg, p.o. bid) results in 62% tumor growth inhibition in PC3M-luc-C6 subcutaneuous local implant xenograft mouse model. ^[4] PF-562,271 (5 mg/kg, oral) results in significant and similar increases in osteocalcin and cancellous bone parameters and a decrease in tumor growth and signs of bone healing in rats implanted with MDA-MB-231 cells in the tibia. ^[5]

Protocol

Animal Research:^[1]	- Collapse Animal Models: Athymic female mice bearing BxPc3 or PC3-M xenografts. Formulation: 5% Gelucire Dosages: 50 mg/kg Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL warmed (197.04 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	5 mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-562271 SDF

Molecular Weight	507.49
Formula	C₂₁H₂₀F₃N₇O₃S
CAS No.	717907-75-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

FAK Signaling Pathway Map

Related FAK Products

PND-1186 (VS-4718) ^New

PND-1186 (VS-4718) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. Phase 1.
PF-431396 ^New

PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.
Defactinib (VS-6063, PF-04554878) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
PF-00562271 Besylate

PF-00562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
TAE226 (NVP-TAE226)

TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.
PF-573228

PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β.
PF-562271 HCl

PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
Dasatinib

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-562271

Cited by 67 Publications

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-562271 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

FAK Signaling Pathway Map

Related FAK Products

Choose Your Country or Region

By Signaling Pathways

By product type

PF-562271

Cited by 67 Publications

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-562271 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

FAK Signaling Pathway Map

Related FAK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)